News

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory processes .

Cerillo and Opentrons are automating microbiome research and the discovery of microbiome therapeutics by seamlessly integrating Cerillo’s miniaturized Alto™ and Stratus® microplate readers onto the OT-2 and Flex for deck ELISA and cell growth analysis. This integration enables easy setup of experiments, including bacterial co­culture studies with Cerillo’s Co-culture platform.

According to Eric Mayton, CEO of Cerillo, “The integration of Cerillo’s products with Opentrons’ platforms aligns with our mission to provide accessible, cost effective, user-friendly laboratory tools that efficiently standardize global microbiome research at the bench. Our alignment with Opentrons’ open-source robotics platform sets new standards for industry efficiency.”

Cerillo’s Microbiome Discovery Platform

The Cerillo Microbiome Discovery Platform offers a comprehensive suite of tools to tackle the challenges of microbiome research head-on. This interconnected platform introduces unprecedented efficiencies, elevating data standardization, reproducibility, and analysis of research findings. Cerillo’s innovative platform includes:

Co-Culture Duet System®: Cerillo’s off-the-shelf microbial interaction platform features duets with porous barriers, allowing researchers to physically isolate populations while maintaining fluidic contact. This enables the observation, study, and growth measurement of individual microbial populations alongside others.

Miniaturized Microplate Readers: Cerillo’s compact microplate readers, like the next-generation Alto™, are ten times smaller than standard ones, perfect for monitoring measurements in tight spaces and anaerobic chambers. Alto is also Ideal for ELISA and high-throughput microbial growth curve applications.

Canopy Wireless Accessory Package: Cerillo’s revolutionary SaaS package offers wireless capabilities and robust software analytics so that researchers can experience real-time data visualization, monitoring, and wireless control of their microplate readers and scale their experiments by connecting multiple readers simultaneously.

 

Learn more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin